USP <800> Compliance Toolkit Formulations

The CPNP USP <800> Compliance Toolkit includes assessments of risk on the formulations listed below. To request additional formulations, simply email the CPNP Office, and they will be considered.

Formulations with Pending Assessments of Risk

To request additional formulations, simply email the CPNP Office, and they will be considered.

We are monitoring the NIOSH 2020 update, but it has yet to be finalized. Once finalized, potential additions to the toolkit include Exenatide, Interferon Beta 1-B, Clobazam, Triazolam, Isotretinoin, and others. While the list remains in draft, these Assessments of Risk will not be developed.

Removed Formulations

The following formulations have been removed from the toolkit due to a change of designation that excludes them from the USP <800> compliance process.

1. Risperidone: Removed from the NIOSH list on 1/10/2019
2. Paliperidone: Removed from the NIOSH list on 1/10/2019

Omitted: Medications NOT Eligible for Assessments of Risk

USP 800 allows an assessment of risk to be completed on all medications on Table 2: Non-antineoplastic Hazardous Drugs and Table 3: Non-antineoplastic Drugs that primarily have adverse reproductive effects. However, for medications on Table 1: Antineoplastic Drugs, an assessment of risk is only allowed if the product is a solid dosage form. For all other medications on Table1: Antineoplastic Drugs, full compliance with all standards in USP 800 is required. Table 1 medications are listed below, but the latest complete list can always be found in the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.